New developments in the prospects for GLP-1 therapy.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Works matching IS 00071188 AND DT 2022 AND VI 179 AND IP 4
Results: 17
1
2
The role of glia in the physiology and pharmacology of glucagon‐like peptide‐1: implications for obesity, diabetes, neurodegeneration and glaucoma.
- Published in:
- British Journal of Pharmacology, 2022, v. 179, n. 4, p. 715, doi. 10.1111/bph.15683
- By:
- Publication type:
- Article
3
Glucagon‐like peptide‐1 (GLP‐1) signalling in the brain: From neural circuits and metabolism to therapeutics.
- Published in:
- British Journal of Pharmacology, 2022, v. 179, n. 4, p. 600, doi. 10.1111/bph.15682
- By:
- Publication type:
- Article
4
The role of glucagon-like peptide 1 (GLP-1) in addictive disorders.
- Published in:
- 2022
- By:
- Publication type:
- journal article
5
Glucagon‐like peptide‐1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?
- Published in:
- British Journal of Pharmacology, 2022, v. 179, n. 4, p. 542, doi. 10.1111/bph.15647
- By:
- Publication type:
- Article
6
Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment.
- Published in:
- British Journal of Pharmacology, 2022, v. 179, n. 4, p. 557, doi. 10.1111/bph.15638
- By:
- Publication type:
- Article
7
Actions of glucagon‐like peptide‐1 receptor ligands in the gut.
- Published in:
- British Journal of Pharmacology, 2022, v. 179, n. 4, p. 727, doi. 10.1111/bph.15611
- By:
- Publication type:
- Article
8
Reappraising the role of the vagus nerve in GLP‐1‐mediated regulation of eating.
- Published in:
- British Journal of Pharmacology, 2022, v. 179, n. 4, p. 584, doi. 10.1111/bph.15603
- By:
- Publication type:
- Article
9
The role of nucleus of the solitary tract glucagon‐like peptide‐1 and prolactin‐releasing peptide neurons in stress: anatomy, physiology and cellular interactions.
- Published in:
- British Journal of Pharmacology, 2022, v. 179, n. 4, p. 642, doi. 10.1111/bph.15576
- By:
- Publication type:
- Article
10
Normalisation of glucose metabolism by exendin‐4 in the chronic phase after stroke promotes functional recovery in male diabetic mice.
- Published in:
- British Journal of Pharmacology, 2022, v. 179, n. 4, p. 677, doi. 10.1111/bph.15524
- By:
- Publication type:
- Article
11
Issue Information.
- Published in:
- British Journal of Pharmacology, 2022, v. 179, n. 4, p. 487, doi. 10.1111/bph.15547
- Publication type:
- Article
12
The diverse effects of brain glucagon‐like peptide 1 receptors on ingestive behaviour.
- Published in:
- British Journal of Pharmacology, 2022, v. 179, n. 4, p. 571, doi. 10.1111/bph.15535
- Publication type:
- Article
13
Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders.
- Published in:
- British Journal of Pharmacology, 2022, v. 179, n. 4, p. 695, doi. 10.1111/bph.15508
- Publication type:
- Article
14
The therapeutic potential of GLP‐1 receptor biased agonism.
- Published in:
- British Journal of Pharmacology, 2022, v. 179, n. 4, p. 492, doi. 10.1111/bph.15497
- Publication type:
- Article
15
Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands.
- Published in:
- British Journal of Pharmacology, 2022, v. 179, n. 4, p. 526, doi. 10.1111/bph.15485
- By:
- Publication type:
- Article
16
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor.
- Published in:
- British Journal of Pharmacology, 2022, v. 179, n. 4, p. 659, doi. 10.1111/bph.15462
- By:
- Publication type:
- Article
17
Non-peptide agonists and positive allosteric modulators of glucagon-like peptide-1 receptors: Alternative approaches for treatment of Type 2 diabetes.
- Published in:
- 2022
- By:
- Publication type:
- journal article